During the height of the COVID-19 pandemic in 2020, 7i Group set out to uncover how cancer services adjusted to the situation and to understand whether the pandemic has been an unlikely catalyst for positive innovation. A short online survey was conducted with a sample of 60 oncologists across Europe (including UK, Spain, Italy, France & Germany).
Oncologists qualified for the survey if they treated and managed one or more of the following tumour types; breast, colorectal, lung, pancreatic, prostate, stomach and liver, representing the more prevalent cancers in Europe 1.
As the pandemic stabilised, a follow-up piece of research was conducted. This research sought to understand further the current challenges oncologists are facing and to assess if the innovations implemented two years ago have become a permanent feature in cancer pathways.